Find clinical documents

or

Document type:
RAG rating:question mark
Place:
Output type:
Medicine / Guideline Indication RAG rating Document type Place
2WW Non-Specific Symptoms pathway with CT Scans n/a Clinical pathways South and West Hertfordshire
Abdomen and Pelvis CT to rule out Pancreatic Cancer n/a Decision document South and West Hertfordshire
Anastrozole Familial breast cancer n/a NICE technology appraisal Hertfordshire and West Essex ICB
Bladder-Renal Cancer | Suspected n/a Clinical pathways Hertfordshire and West Essex ICB
Brain and Central Nervous System Cancers n/a Clinical pathways East and North Hertfordshire
Brain MRI for the exclusion of Brain and CNS Cancer n/a n/a South and West Hertfordshire
Breast Cancer - Suspected (Adults >16 years) n/a Clinical pathways Hertfordshire and West Essex ICB
Breast Screening Service n/a Patient information Hertfordshire and West Essex ICB
Cannabidiol (Epidiyolex®) Tertiary care indication (NHSE) Suitable for shared care between tertiary and secondary care providers. Adjunctive treatment with clobazam for treating seizures associated with Dravet syndrome and Lennox-Gastaut syndrome (LGS) Red Decision document Hertfordshire and West Essex ICB
Children's Cancer n/a Patient information Hertfordshire and West Essex ICB
Chlorambucil Cancer indications Red n/a Hertfordshire and West Essex ICB
Chlormethine gel Mycosis fungoides-type cutaneous T-cell lymphoma (NHSE) Red NICE technology appraisal Hertfordshire and West Essex ICB
Community Breast Pain n/a Clinical pathways East and North Hertfordshire
CT Request and 2WW Non-Specific Symptoms Referral Pathway n/a Clinical pathways South and West Hertfordshire
Dasatinib Cancer (NHSE) Red Decision document Hertfordshire and West Essex ICB
Delta-9-tetrahydrocannabinol [THC] and cannabidiol [CBD] spray (Sativex®) Spasticity in multiple sclerosis (MS) Red Decision document Hertfordshire and West Essex ICB
Denosumab Xgeva® Prevention of skeletal-related events (NHSE) Red NICE technology appraisal Hertfordshire and West Essex ICB
Erlotinib All indications (NHSE) Red n/a Hertfordshire and West Essex ICB
Etoposide Cancer (NHSE) Red Decision document Hertfordshire and West Essex ICB
Exemestane Familial breast cancer Amber initiation NICE technology appraisal Hertfordshire and West Essex ICB
Faecal Immunochemical Test (FIT) process pathway for suspected Lower GI Cancer n/a Clinical pathways Hertfordshire and West Essex ICB, South and West Hertfordshire
Fulvestrant Locally advanced or metastatic breast cancer Double Red NICE technology appraisal Hertfordshire and West Essex ICB
Goserelin Prostate cancer - 2nd line Amber initiation n/a Hertfordshire and West Essex ICB
Gynaecological Cancers - Suspected n/a Clinical pathways Hertfordshire and West Essex ICB
Haematological Cancer – Suspected n/a Clinical pathways Hertfordshire and West Essex ICB
Head and Neck Cancer - Suspected n/a Clinical pathways East and North Hertfordshire
Ibandronic acid 50mg Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. Amber initiation n/a Hertfordshire and West Essex ICB
Ibrutinib Cancer (NHSE) Red Decision document Hertfordshire and West Essex ICB
Imatinib All indications (NHSE) Red Decision document Hertfordshire and West Essex ICB
Lenalidomide Multiple myeloma follicular lymphoma (NHSE) Red NICE technology appraisal Hertfordshire and West Essex ICB
Letrozole Familial breast cancer Amber initiation NICE technology appraisal Hertfordshire and West Essex ICB
Leuprorelin Prostate cancer - 2nd line Amber initiation n/a Hertfordshire and West Essex ICB
Lower GI/Colorectal Cancer Suspected n/a Clinical pathways East and North Hertfordshire, South and West Hertfordshire
Lung Cancer - Suspected n/a Clinical pathways East and North Hertfordshire, South and West Hertfordshire
Lymphoedema Services – Specialist treatment in the private sector n/a Clinical policy Hertfordshire and West Essex ICB
Male LUTS n/a Clinical pathways Hertfordshire and West Essex ICB
Melphalan Cancer (NHSE) Red Decision document Hertfordshire and West Essex ICB
Mesna Cancer (NHSE) Red Decision document Hertfordshire and West Essex ICB
Methotrexate 10mg Autoimmune disease Double Red n/a Hertfordshire and West Essex ICB
Methotrexate 2.5mg Autoimmune disease Amber protocol Prescribing guideline Hertfordshire and West Essex ICB
Methoxsalen Cancer, psoriasis Red n/a Hertfordshire and West Essex ICB
Mitomycin Cancer (NHSE) Red Decision document Hertfordshire and West Essex ICB
Mitotane Cancer (NHSE) Red Decision document Hertfordshire and West Essex ICB
Nabilone Intractable chemotherapy induced nausea and vomiting Red Decision document Hertfordshire and West Essex ICB
Nintedanib Cancer (NHSE) Red Decision document Hertfordshire and West Essex ICB
Palbociclib Cancer (NHSE) Red Decision document Hertfordshire and West Essex ICB
Peginterferon and ropeginterferon Myeloproliferative neoplasms (NHSE) Red Decision document Hertfordshire and West Essex ICB
Pegvisomant Acromegaly (NHSE tertiary centre only) Red Prescribing guideline Hertfordshire and West Essex ICB
Prostate Cancer - Suspected n/a Clinical pathways Hertfordshire and West Essex ICB
PSA Pathway n/a Clinical pathways Hertfordshire and West Essex ICB
Raloxifene Familial breast cancer Amber initiation NICE technology appraisal Hertfordshire and West Essex ICB
Reducing medicines waste in care homes - Care home staff Care homes n/a Prescribing support document Hertfordshire and West Essex ICB
Relugolix (Orgovyx) Hormone-sensitive prostate cancer Red NICE technology appraisal Hertfordshire and West Essex ICB
Ruxolitinib Myelofibrosis (NHSE) Red NICE technology appraisal Hertfordshire and West Essex ICB
Sarcoma - Suspected Cancer n/a Clinical pathways East and North Hertfordshire
Sativex® and other licensed cannabis -based medicinal products Red Decision document Hertfordshire and West Essex ICB
Sirolimus oral Transplant rejection (prescribe by brand) NHSE for existing patients Amber protocol n/a Hertfordshire and West Essex ICB
Skin Cancer Suspected - Pigmented Lesion/ Melanoma/ SCC/ BCC n/a Patient information Hertfordshire and West Essex ICB
Sodium clodronate Bone pain, hypercalcaemia of malignancy Amber initiation n/a Hertfordshire and West Essex ICB
Tacrolimus oral Transplant rejection (prescribe by brand) NHSE for existing patients Amber protocol n/a Hertfordshire and West Essex ICB
Tamoxifen Familial breast cancer Amber initiation NICE technology appraisal Hertfordshire and West Essex ICB
Thalidomide Cancer (NHSE) Red Decision document Hertfordshire and West Essex ICB
Tioguanine Leukaemia Red n/a Hertfordshire and West Essex ICB
Tretinoin Cancer (NHSE) Red n/a Hertfordshire and West Essex ICB
Triptorelin as Decapeptyl SR®– Gonadorelin analogue of choice within licensed indications Prostate cancer - 1st line Green n/a Hertfordshire and West Essex ICB
Urology Cancer - Suspected (excluding Prostate) n/a Clinical pathways Hertfordshire and West Essex ICB